
SOTS 2nd Hour: Alphabet’s Revenue Miss, Musk’s Role in Government, Live: Shell CEO 02/05/25
Squawk on the Street
00:00
Novo Nordisk's Profitable Surge Amidst Stock Struggles
This chapter explores Novo Nordisk's impressive Q4 profits driven by high demand for its WeGoVe obesity drug, which achieved a 107% sales increase. Despite this surge, the company's stock has fallen over 25% for the year, creating a challenging landscape for investors.
Transcript
Play full episode